Structure Therapeutics (NASDAQ:GPCR) Earns Outperform Rating from Analysts at William Blair

Research analysts at William Blair assumed coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The firm set an “outperform” rating on the stock.

Other equities research analysts have also issued research reports about the stock. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $22.82 on Friday. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -30.84 and a beta of -2.75. The firm has a 50-day moving average price of $26.66 and a two-hundred day moving average price of $33.66. Structure Therapeutics has a 52 week low of $19.61 and a 52 week high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, sell-side analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after buying an additional 312 shares in the last quarter. Virtus ETF Advisers LLC increased its holdings in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after acquiring an additional 455 shares during the period. ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares in the last quarter. LPL Financial LLC boosted its holdings in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock valued at $311,000 after purchasing an additional 646 shares during the period. Finally, Assetmark Inc. boosted its holdings in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.